AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Abstract Text:

Ascan Warnholtz,Mir Abolfazl Ostad,Thomas Heitzer,Felix Thuneke,Meike ,Peter Tschentscher,Edzard Schwedhelm,Rainer ,Thomas Meinertz,Thomas Munzel,Ascan Warnholtz,Mir Abolfazl Ostad,Thomas Heitzer,Felix Thuneke,Meike ,Peter Tschentscher,Edzard Schwedhelm,Rainer ,Thomas Meinertz,Thomas Munzel,

Activation of the renin-angiotensin-aldosterone system plays an important role in the pathogenesis of endothelial dysfunction and atherosclerosis. Studies evaluating the effect of AT1-receptor blockers on endothelial dysfunction in patients with coronary artery disease (CAD) revealed mixed results. Studies addressing the effects of AT1-receptor blockers on the coronary and peripheral function in the same study population, are still lacking. We therefore aimed to test the effects of long-term therapy with the AT1-receptor blocker irbesartan (IRB) on both, the coronary and peripheral endothelial function in patients with CAD. Seventy-two patients with CAD were randomly assigned to double-blinded treatment for 6 months with IRB 300 mg per day or placebo, respectively. Coronary and peripheral endothelial function were measured by intracoronary infusion of acetylcholine (final intracoronary concentration 10(-7.3) to 10(-5.6)M) and by determining flow-dependent dilation (FMD) of the brachial artery, respectively. IRB significantly improved FMD, while no change of coronary endothelial function was observed. Interestingly, plasma levels of N(G),N(G)-dimethyl-arginine, and the isoprostane excretion rate were not modified. IRB treatment improves peripheral but not coronary endothelial dysfunction in patients with CAD. Since reduced FMD of the brachial artery has been shown to be associated with a high-cardiovascular event rate, improvement of FMD by IRB may lead to better prognosis of patients with CAD.

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Publishing Authors By Initials

A Warnholtz,MA Ostad,T Heitzer,F Thuneke,M ,P Tschentscher,E Schwedhelm,R ,T Meinertz,T Munzel,A Warnholtz,MA Ostad,T Heitzer,F Thuneke,M ,P Tschentscher,E Schwedhelm,R ,T Meinertz,T Munzel,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Atherosclerosis

VOLUME: 194

Page Numbers: 439-45

Journal Abbreviation: Atherosclerosis

ISSN: 0021-9150

DAY: 12

MONTH: 09

YEAR: 2006

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 242543

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.

AFFILIATION: Department of Medicine II, Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. warnholt@uni-mainz.de

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Atherosclerosis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease Related Publications

• A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study.
• AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.
• Improvement of asthma therapy by a novel formoterol multidose dry powder inhaler.
• [Applications of rheology (study of the flow of liquids) in pharmacology.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]